|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_1455 | ED149609 | General Research Use | No | Female | White | 71 | 4 - AREDS AMD Severity Scale Step 2 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2990 | ED149543 | General Research Use | No | Female | White | 60 | 4 - AREDS AMD Severity Scale Step 3 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_3752 | ED148923 | General Research Use | No | Male | White | 75 | 4 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_4056 | ED149401 | General Research Use | No | Male | White | 79 | 4 - AREDS AMD Severity Scale Step 4 | 4 - AREDS AMD Severity Scale Step 4 |
| AR2_0544 | ED149524 | General Research Use | No | Female | White | 83 | 4 - AREDS AMD Severity Scale Step 2 | 3 - AREDS AMD Severity Scale Step 3 |
| AR2_1264 | ED149174 | General Research Use | No | Female | White | 77 | 4 - AREDS AMD Severity Scale Step 4 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3591 | ED149127 | General Research Use | No | Male | White | 64 | 4 - AREDS AMD Severity Scale Step 2 | 4 - AREDS AMD Severity Scale Step 4 |
| AR2_3671 | ED148715 | General Research Use | No | Female | White | 81 | 4 - AREDS AMD Severity Scale Step 3 | 3 - AREDS AMD Severity Scale Step 3 |
| AR2_0618 | ED148191 | General Research Use | No | Male | White | 68 | 4 - AREDS AMD Severity Scale Step 4 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0722 | ED148703 | General Research Use | No | Male | White | 59 | 4 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_2716 | ED149234 | General Research Use | No | Female | White | 74 | 4 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_0725 | ED149302 | General Research Use | No | Female | White | 73 | 4 - AREDS AMD Severity Scale Step 4 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1342 | ED148036 | General Research Use | No | Female | White | 71 | 4 - AREDS AMD Severity Scale Step 2 | 4 - AREDS AMD Severity Scale Step 4 |
| AR2_1502 | ED148779 | General Research Use | No | Male | White | 78 | 4 - AREDS AMD Severity Scale Step 4 | 3 - AREDS AMD Severity Scale Step 3 |
| AR2_2686 | ED149764 | General Research Use | No | Female | White | 72 | 4 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_2991 | ED148417 | General Research Use | No | Male | Native Hawaiian or other Pacific | 59 | 4 - AREDS AMD Severity Scale Step 4 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_3116 | ED148679 | General Research Use | No | Female | White | 76 | 4 - AREDS AMD Severity Scale Step 3 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_3420 | ED149848 | General Research Use | No | Male | White | 81 | 4 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3453 | ED148326 | General Research Use | No | Female | White | 78 | 4 - AREDS AMD Severity Scale Step 4 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3512 | ED149678 | General Research Use | No | Male | White | 74 | 4 - AREDS AMD Severity Scale Step 2 | 5 - AREDS AMD Severity Scale Step 5 |